OnKure Therapeutics announced its Q2 2026 financial results, highlighting progress in its next-generation PI3Kα pan-mutant selective inhibitors OKI-345 for breast cancer and OKI-355 for vascular anomalies. Both candidates are undergoing IND-enabling activities with planned FDA submissions in the first half of 2027. The company held a Key Opinion Leader event to emphasize the scientific rationale behind its targeted therapies and showcased at the ISSVA World Congress 2026. With $176 million in cash and equivalents, OnKure expects to fund operations into 2029, positioning itself to develop differentiated treatments for PI3Kα-driven diseases.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
The Vanguard Information Technology ETF (VGT) excludes major tech-adjacent companies like Alphabet (Google), Meta, and Amazon due to a 2018 sector reclassification that moved these firms out of the Information Technology sector. Instead, VGT focuses ...
